A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC）

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06461156
• Other study ID #: HS-10504-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 30, 2024
• Est. completion date: March 31, 2027

Study information

• Verified date: June 2024
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: Jianxing He, PhD
• Phone: 020-83062807
• Email: drjianxing_he1[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 230
• Est. completion date: March 31, 2027
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or females, aged = 18 years.
• Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC
• Progressive disease on or after prior treatment with EGFR-TKIs.
• Enrollment will be restricted to participants with evidence of EGFR-positive in tumor as determined by local or central testing.
• At least 1 target lesion according to RECIST 1.1.
• ECOG PS score: 0-1.
• Estimated life expectancy> 12 weeks.
• Men or women should be using adequate contraceptive measures throughout the study.
• Women must have the evidence of non-childbearing potential.
• Signed and dated Informed Consent Form.

Exclusion Criteria:

• Subjects with known oncogenic driver genes other than EGFR.
• Subjects with mixed cell histologic or with phenotypic transformation.
• Treatment with any of the following:

1. Prior or concurrent treatment with fourth-generation EGFR tyrosine kinase inhibitors.

2. Cytotoxic chemotherapy, any other investigational drugs, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days prior to the first dose of HS-10504 or require continued treatment with these drugs during the study.

3. Any local radiotherapy 2 weeks prior to the first dose of study treatment; have received irradiation of more than 30% of bone marrow prior to the first dose

4. Uncontrolled pleural effusion or ascites or pericardial effusion.

5. Major surgery within 4 weeks before the first dose.

6. CNS metastases with symptomatic or active progression.

• Subjects who have any grade =2 residual toxicities from prior therapies.
• Subjects who have history of other primary malignancies.
• Inadequate bone marrow reserve or hepatic and renal functions.
• Subjects with severe or poorly controlled diabetes, cardiovascular diseases or hypertension; subjects with severe arteriovenous thrombotic events, severe infection, clinically significant bleeding symptoms or clinically significant gastrointestinal dysfunction.
• Hypersensitivity to any ingredient of HS-10504.
• Moderate to severe pulmonary diseases.
• Prior history of significant neurological or mental disorders.
• Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
• Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
• Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Locally Advanced or Metastatic NSCLC

Intervention

Drug:
• HS-10504
HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the maximum tolerated dose (MTD) or the maximum applicable dose (MAD)	To determine the MTD or MAD for further evaluation of oral administration of HS-10504 in subjects with NSCLC	From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (21 days).
Secondary	Incidence and severity of adverse events (AEs).	Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.	From the first dose until 28 days after the last dose
Secondary	maximum plasma concentration (Cmax) of HS-10504 (and its major matabolite) for the first dose and multiple dose adminitration of HS-10504	Cmax is the maximum observed concentration	From the first dose until Circle 2 Day 1
Secondary	Time to reach maximum plasma concentration (Tmax) for the first dose and multiple adminitration of HS-10504 (and its major matabolite)	Tmax is defined as time to reach maximum observed plasma concentration	From the first dose until Circle 2 Day 1
Secondary	half-life (T1/2) of HS-10504 (and its major matabolite) for the first dose and multiple dose adminitration of HS-10504	half-life is the time measured for the concentration to decrease by one half	From the first dose until Circle 2 Day 1
Secondary	Area under the curve (AUC) of HS-10504 (and its major matabolite) for the first dose and multiple dose adminitration of HS-10504	The AUC is defined as the area under the plasma concentration-time curve	From the first dose until Circle 2 Day 1
Secondary	Trough plasma concentration (Ctrough) of HS-10504 (and its major matabolite)	Ctrough is the observed plasma concentration immediately prior to the next dose administration	From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months
Secondary	Objective response rate (ORR)	ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	up to 24 months
Secondary	Disease Control Rate (DCR)	Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline. DCR was evaluated by the number of participants with best overall response of CR, PR and stable disease (SD)	up to 24 months
Secondary	Duration of response (DOR)	Duration of response (DoR) determined by investigators according to RECIST 1.1. DoR was defined as the period from the first occurrence of CR or PR to progressive disease (PD) or death from any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) would be used	up to 24 months
Secondary	Progression-free survival (PFS)	Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was de?ned as the time from date of ?rst dose until the documentation of objective PD or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.	From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months
Secondary	Overall survival (OS), only for dose-expansion stage subjects	OS was defined as the time from the first dose or random assignment (if any) to death from any cause	From the first dose up to death or withdrawal from study, whichever came first, assessed up to 24 months